ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrated transcriptomic and Mendelian randomization analysis identifies novel biomarkers for type 2 diabetes-associated cardiac dysfunction: cynaropicrin as a candidate intervention.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to identify T2DM-associated biomarkers linked to diabetic cardiac dysfunction-related transcriptomic signatures through integrated transcriptomic and Mendelian randomization analysis and evaluate cynaropicrin as a candidate cardiometabolic intervention. Transcriptomic datasets from the GEO database related to diabetic cardiac dysfunction, heart failure, and cardiomyopathy-associated phenotypes were processed for differential expression analysis and WGCNA, with consideration of disease-definition and tissue-source heterogeneity. A two-sample Mendelian randomization analysis was used to evaluate genetically predicted associations between candidate gene expression and T2DM risk. External validation assessed diagnostic performance via ROC analysis. Multi-database screening and molecular docking identified candidate compounds. Streptozotocin-induced diabetic rats were treated with cynaropicrin for 8 weeks, with comprehensive cardiac and metabolic assessment. Analysis identified 30 candidate genes with functional enrichment in proteostasis and metabolism. Mendelian randomization prioritized three T2DM-associated genetically supported genes: PPIP5K2, RBM23, and IGF2BP2. Cynaropicrin significantly improved cardiac function, reduced fibrosis, and enhanced glycemic control in diabetic rats while suppressing pro-fibrotic signaling. PPIP5K2, RBM23, and IGF2BP2 represent T2DM-associated genetically supported biomarkers dysregulated in diabetic cardiac dysfunction-related datasets with diagnostic potential. Cynaropicrin demonstrates candidate cardioprotective and metabolic benefits in diabetic rats; however, its direct molecular targets and mechanism of action require further validation.
Indexed as
Identifiers
42429831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.